Godavari Biorefineries Limited has informed the Exchange about Investor Presentation
GODAVARIB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Godavari Biorefineries Limited reported Total Income of ₹2,000.2 Crs (up 6% YoY) and EBITDA of ₹139.3 Crs (up 15.8% YoY) with margins improving to 7.0% from 6.4% in FY25. Finance costs dropped 31.6% to ₹49.1 Crs following ₹240 Crs debt repayment. Bio-based Chemicals segment grew 6.6% to ₹578 Crs with EBITDA margins improving to 8.3% (from 7.0%) driven by a richer specialty chemicals mix (58% vs 42% in FY25). Ethanol revenue rose 12.6% to ₹658.6 Crs with 98 million litres sold. A new 200 KLPD grain-based distillery is on track to commission by June 2026, adding 60 MnL of annual ethanol capacity. The company also highlighted its expansion into drug discovery (via subsidiary Sathgen Therapeutics) and green chemistry partnerships (Synthomer, Catalyxx) alongside its DME pilot project with ICT.
Margin improvement in Bio-based Chemicals and significant debt reduction signal improving operational efficiency and financial health. The specialty chemicals portfolio shift is a positive structural change for long-term profitability. New ethanol capacity and policy tailwinds (E20+, E85/E100 standards) position the company well for volume growth.